<p>Lifecore Biomedical（纳斯达克代码：LFCR - 获取免费报告）可能将在 4 月 2 日星期四市场收盘后公布其业绩。分析师预计该公司本季度每股收益为（$0.27），收入为 2595.70 万美元。</p>
<p>Lifecore Biomedical（纳斯达克代码：LFCR - 获取免费报告）最近一次发布季度财报是在 3 月 16 日星期一。该公司报告本季度每股收益（EPS）为（$0.16），低于市场共识预期的（$0.11），差距为（$0.05）。该公司本季度收入为 3575 万美元，高于市场共识预期的 3531 万美元。Lifecore Biomedical 的股本回报率为负的 1211.09%，净利润率为负的 23.08%。分析师平均预计 Lifecore Biomedical 在当前财年每股收益为-$1，在下一个财年每股收益也为-$1。</p>
<p>获取 <strong>Lifecore Biomedical</strong> 的提醒：</p>
<h2>Lifecore Biomedical 价格表现</h2>
<p>Lifecore Biomedical 的股票在星期五开盘价为$3.87。该公司的债务与股本比率为 113.76，流动比率为 2.80，速动比率为 1.67。Lifecore Biomedical 的股价一年低点为$3.86，一年高点为$8.98。该公司的 50 日简单移动平均为$6.95，200 日简单移动平均为$7.29。该股票的市值为 1.4505 亿美元，市盈率为-3.95，贝塔值为 0.62。</p>
<h2>机构投资者对 Lifecore Biomedical 的看法</h2>
<p>一些大型投资者最近对 LFCR 的持仓进行了调整。Quarry LP 在第三季度购买了 Lifecore Biomedical 的新股份，价值约为$28,000。BNP Paribas 金融市场在第三季度增持了 Lifecore Biomedical 的股份，增幅为 92.7%。BNP Paribas 金融市场现在拥有 5791 股该公司的股票，价值$43,000，此前在上个季度增持了 2786 股。怀俄明州购买了 Lifecore Biomedical 的新股份，价值为$69,000。制造商人寿保险公司在第二季度购买了 Lifecore Biomedical 的新股份，价值为$88,000。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度增持了 Lifecore Biomedical 的股份，增幅为 14.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 14785 股该公司的股票，价值为$104,000，此前在此期间增持了 1886 股。当前 83.36% 的股票由机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位研究分析师最近对 LFCR 股票发表了评论。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Lifecore Biomedical 股票的 “卖出（d）” 评级。Barrington Research 在周二重新发布了 “跑赢大盘” 评级，并设定了 Lifecore Biomedical 股票的目标价为$5.50。最后，Zacks Research 在 1 月 1 日的报告中将 Lifecore Biomedical 的股票评级提升至 “持有”。两位研究分析师给予该股票买入评级，两位给予持有评级，一位给予卖出评级。根据 MarketBeat.com 的数据，Lifecore Biomedical 的平均评级为 “持有”，共识目标价为$5.50。</p>
<p><strong>查看我们关于 Lifecore Biomedical 的最新报告</strong></p>
<h2>关于 Lifecore Biomedical</h2>
<p>（获取免费报告）</p>
<p>Lifecore Biomedical, Inc 是一家公开交易的专业生物制药公司，总部位于明尼苏达州查斯卡。该公司专注于开发、制造和商业化基于透明质酸（HA）的产品，以满足医疗和美容需求。Lifecore 的专有 HA 配方旨在满足高度监管市场对纯度、一致性和性能的严格监管标准。</p>
<p>该公司的产品组合涵盖多个治疗领域，包括眼科、骨科、皮肤科和伤口护理。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Lifecore Biomedical</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Lifecore Biomedical 吗？</h2>
<p>在你考虑 Lifecore Biomedical 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Lifecore Biomedical 并不在名单上。</p>
<p>虽然 Lifecore Biomedical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LFCR

<p>Lifecore Biomedical（纳斯达克代码：LFCR）定于 4 月 2 日星期四市场收盘后发布财报。分析师预测该季度每股亏损 0.27 美元，收入为 2596 万美元。该公司此前报告每股亏损 0.16 美元，收入为 3575 万美元。Lifecore 的市值为 1.4505 亿美元，市盈率为-3.95。机构投资者持有 83.36% 的股份，各种分析师的评级从 “买入” 到 “卖出” 不等。平均评级为 “持有”，目标价格为 5.50 美元</p>

<p>Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) will likely be announcing its results after the market closes on Thursday, April 2nd. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $25.9570 million for the quarter.</p>
<div class="lb-trans"><p>Lifecore Biomedical（纳斯达克代码：LFCR - 获取免费报告）可能将在 4 月 2 日星期四市场收盘后公布其业绩。分析师预计该公司本季度每股收益为（$0.27），收入为 2595.70 万美元。</p>
</div><p>Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $35.75 million for the quarter, compared to the consensus estimate of $35.31 million. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Lifecore Biomedical（纳斯达克代码：LFCR - 获取免费报告）最近一次发布季度财报是在 3 月 16 日星期一。该公司报告本季度每股收益（EPS）为（$0.16），低于市场共识预期的（$0.11），差距为（$0.05）。该公司本季度收入为 3575 万美元，高于市场共识预期的 3531 万美元。Lifecore Biomedical 的股本回报率为负的 1211.09%，净利润率为负的 23.08%。分析师平均预计 Lifecore Biomedical 在当前财年每股收益为-$1，在下一个财年每股收益也为-$1。</p>
</div><p>Get <strong>Lifecore Biomedical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lifecore Biomedical</strong> 的提醒：</p>
</div><h2>Lifecore Biomedical Price Performance</h2>
<div class="lb-trans"><h2>Lifecore Biomedical 价格表现</h2>
</div><p>Shares of Lifecore Biomedical stock opened at $3.87 on Friday. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. Lifecore Biomedical has a one year low of $3.86 and a one year high of $8.98. The business's 50 day simple moving average is $6.95 and its two-hundred day simple moving average is $7.29. The stock has a market capitalization of $145.05 million, a P/E ratio of -3.95 and a beta of 0.62.</p>
<div class="lb-trans"><p>Lifecore Biomedical 的股票在星期五开盘价为$3.87。该公司的债务与股本比率为 113.76，流动比率为 2.80，速动比率为 1.67。Lifecore Biomedical 的股价一年低点为$3.86，一年高点为$8.98。该公司的 50 日简单移动平均为$6.95，200 日简单移动平均为$7.29。该股票的市值为 1.4505 亿美元，市盈率为-3.95，贝塔值为 0.62。</p>
</div><h2>Institutional Investors Weigh In On Lifecore Biomedical</h2>
<div class="lb-trans"><h2>机构投资者对 Lifecore Biomedical 的看法</h2>
</div><p>A number of large investors have recently made changes to their positions in LFCR. Quarry LP bought a new position in shares of Lifecore Biomedical during the third quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its holdings in Lifecore Biomedical by 92.7% in the third quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company's stock valued at $43,000 after acquiring an additional 2,786 shares in the last quarter. State of Wyoming bought a new stake in Lifecore Biomedical in the second quarter valued at $69,000. The Manufacturers Life Insurance Company purchased a new position in Lifecore Biomedical during the 2nd quarter valued at $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Lifecore Biomedical by 14.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock valued at $104,000 after purchasing an additional 1,886 shares during the period. 83.36% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些大型投资者最近对 LFCR 的持仓进行了调整。Quarry LP 在第三季度购买了 Lifecore Biomedical 的新股份，价值约为$28,000。BNP Paribas 金融市场在第三季度增持了 Lifecore Biomedical 的股份，增幅为 92.7%。BNP Paribas 金融市场现在拥有 5791 股该公司的股票，价值$43,000，此前在上个季度增持了 2786 股。怀俄明州购买了 Lifecore Biomedical 的新股份，价值为$69,000。制造商人寿保险公司在第二季度购买了 Lifecore Biomedical 的新股份，价值为$88,000。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度增持了 Lifecore Biomedical 的股份，增幅为 14.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 14785 股该公司的股票，价值为$104,000，此前在此期间增持了 1886 股。当前 83.36% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research analysts recently commented on LFCR shares. Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Lifecore Biomedical in a research note on Thursday, January 22nd. Barrington Research reissued an &#34;outperform&#34; rating and set a $5.50 price target on shares of Lifecore Biomedical in a research report on Tuesday. Finally, Zacks Research raised shares of Lifecore Biomedical to a &#34;hold&#34; rating in a report on Thursday, January 1st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Lifecore Biomedical has an average rating of &#34;Hold&#34; and a consensus target price of $5.50.</p>
<div class="lb-trans"><p>几位研究分析师最近对 LFCR 股票发表了评论。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Lifecore Biomedical 股票的 “卖出（d）” 评级。Barrington Research 在周二重新发布了 “跑赢大盘” 评级，并设定了 Lifecore Biomedical 股票的目标价为$5.50。最后，Zacks Research 在 1 月 1 日的报告中将 Lifecore Biomedical 的股票评级提升至 “持有”。两位研究分析师给予该股票买入评级，两位给予持有评级，一位给予卖出评级。根据 MarketBeat.com 的数据，Lifecore Biomedical 的平均评级为 “持有”，共识目标价为$5.50。</p>
</div><p><strong>View Our Latest Report on Lifecore Biomedical</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Lifecore Biomedical 的最新报告</strong></p>
</div><h2>About Lifecore Biomedical</h2>
<div class="lb-trans"><h2>关于 Lifecore Biomedical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.</p>
<div class="lb-trans"><p>Lifecore Biomedical, Inc 是一家公开交易的专业生物制药公司，总部位于明尼苏达州查斯卡。该公司专注于开发、制造和商业化基于透明质酸（HA）的产品，以满足医疗和美容需求。Lifecore 的专有 HA 配方旨在满足高度监管市场对纯度、一致性和性能的严格监管标准。</p>
</div><p>The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.</p>
<div class="lb-trans"><p>该公司的产品组合涵盖多个治疗领域，包括眼科、骨科、皮肤科和伤口护理。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Lifecore Biomedical</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Lifecore Biomedical</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFCR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lifecore Biomedical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Lifecore Biomedical 吗？</h2>
</div><p>Before you consider Lifecore Biomedical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Lifecore Biomedical 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Lifecore Biomedical 并不在名单上。</p>
</div><p>While Lifecore Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lifecore Biomedical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lifecore Biomedical (LFCR) 将在周四公布财报